DK3455625T3 - PROCEDURES FOR PREDICTING THE APPLICABILITY OF NEO ANTENGES FOR IMMUNTERAPHY - Google Patents

PROCEDURES FOR PREDICTING THE APPLICABILITY OF NEO ANTENGES FOR IMMUNTERAPHY Download PDF

Info

Publication number: DK3455625T3
Authority: DK; Denmark
Prior art keywords: immunteraphy; antenges; neo; predicting; applicability
Prior art date: 2016-05-13

Application number

DK17726208.6T

Other languages

Danish (da)

Inventor

Ugur Sahin

Barbara Schrörs

Sebastian Boegel

Martin Löwer

Mathias Vormehr

Original Assignee

Biontech Rna Pharmaceuticals Gmbh

Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-05-13

Filing date

2017-05-10

Publication date

2020-10-26

2017-05-10 Application filed by Biontech Rna Pharmaceuticals Gmbh, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh

2020-10-26 Application granted granted Critical

2020-10-26 Publication of DK3455625T3 publication Critical patent/DK3455625T3/en

Links

238000000034 method Methods 0.000 title 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Toxicology (AREA)
Zoology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Oncology (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)

DK17726208.6T 2016-05-13 2017-05-10 PROCEDURES FOR PREDICTING THE APPLICABILITY OF NEO ANTENGES FOR IMMUNTERAPHY DK3455625T3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/EP2016/060897 WO2017194170A1 (en)	2016-05-13	2016-05-13	Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
PCT/EP2017/061196 WO2017194610A1 (en)	2016-05-13	2017-05-10	Methods for predicting the usefulness of proteins or protein fragments for immunotherapy

Publications (1)

Publication Number	Publication Date
DK3455625T3 true DK3455625T3 (en)	2020-10-26

Family

ID=55971007

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK20193183.9T DK3792628T3 (en)	2016-05-13	2017-05-10	METHODS FOR PREDICTING THE USEFULNESS OF NEOANTIGENS FOR IMMUNE THERAPY
DK17726208.6T DK3455625T3 (en)	2016-05-13	2017-05-10	PROCEDURES FOR PREDICTING THE APPLICABILITY OF NEO ANTENGES FOR IMMUNTERAPHY

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK20193183.9T DK3792628T3 (en)	2016-05-13	2017-05-10	METHODS FOR PREDICTING THE USEFULNESS OF NEOANTIGENS FOR IMMUNE THERAPY

Country Status (26)

Country	Link
US (1)	US20190178871A1 (en)
EP (3)	EP4411376A2 (en)
JP (4)	JP7529381B2 (en)
KR (3)	KR20220020993A (en)
CN (1)	CN109073637A (en)
AU (2)	AU2017264546B2 (en)
BR (1)	BR112018073221A2 (en)
CA (1)	CA3022654A1 (en)
CY (1)	CY1123520T1 (en)
DK (2)	DK3792628T3 (en)
ES (2)	ES2826480T3 (en)
FI (1)	FI3792628T3 (en)
HR (2)	HRP20240704T1 (en)
HU (2)	HUE067497T2 (en)
IL (2)	IL300841A (en)
LT (2)	LT3792628T (en)
MA (1)	MA43794B1 (en)
MD (1)	MD3455625T2 (en)
MX (2)	MX2018013081A (en)
PL (2)	PL3792628T3 (en)
PT (2)	PT3455625T (en)
RS (2)	RS65568B1 (en)
SG (1)	SG11201808495SA (en)
SI (2)	SI3455625T1 (en)
WO (2)	WO2017194170A1 (en)
ZA (1)	ZA201805809B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108495649A (en)	2016-01-08	2018-09-04	瓦西博迪公司	The new epiposition vaccine of therapeutic anti-cancer
US12072337B2 (en)	2017-05-30	2024-08-27	Nant Holdings Ip, Llc	Circulating tumor cell enrichment using neoepitopes
CN111788214B (en) *	2018-02-15	2021-06-22	国立大学法人旭川医科大学	Cancer antigen peptides
CN109021062B (en) *	2018-08-06	2021-08-20	倍而达药业（苏州）有限公司	Screening method of tumor neoantigen
CN111621564B (en) *	2019-02-28	2022-03-25	武汉大学	Method for identifying effective tumor neoantigen
US20220154281A1 (en) *	2019-03-06	2022-05-19	Gritstone Bio, Inc.	Identification of neoantigens with mhc class ii model
CN110534156B (en) *	2019-09-02	2022-06-17	深圳市新合生物医疗科技有限公司	Method and system for extracting immunotherapy new antigen
CN111487399B (en) *	2020-03-26	2021-09-17	湖南师范大学	Application of protein molecular marker in research on fish germ cell development
EP4392140A1 (en)	2021-08-24	2024-07-03	BioNTech SE	In vitro transcription technologies
WO2024083345A1 (en)	2022-10-21	2024-04-25	BioNTech SE	Methods and uses associated with liquid compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2766205B1 (en) *	1997-07-16	2002-08-30	Inst Nat Sante Rech Med	NOVEL METHOD FOR SENSITIZING ANTIGEN PRESENTING CELLS AND NOVEL MEANS FOR IMPLEMENTING THE METHOD
CA2603191A1 (en) *	2005-03-29	2006-10-05	The Board Of Trustees Of The University Of Illinois	Cancer vaccines and therapeutic methods
JP2009273377A (en) *	2008-05-12	2009-11-26	Igaku Seibutsugaku Kenkyusho:Kk	Method for selecting candidate peptide presented on surface of cancer cell following binding to mhc class i molecule
TW201000119A (en) *	2008-06-10	2010-01-01	Oncotherapy Science Inc	MYBL2 epitope peptides and vaccines containing the same
PL2172211T3 (en) *	2008-10-01	2015-05-29	Immatics Biotechnologies Gmbh	Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
US20110274723A1 (en) *	2009-10-23	2011-11-10	Mannkind Corporation	Cancer immunotherapy and method of treatment
US9266922B2 (en) *	2011-06-01	2016-02-23	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Antigen peptide and uses thereof

2016
- 2016-05-13 WO PCT/EP2016/060897 patent/WO2017194170A1/en active Application Filing
2017
- 2017-05-10 MA MA43794A patent/MA43794B1/en unknown
- 2017-05-10 PL PL20193183.9T patent/PL3792628T3/en unknown
- 2017-05-10 HR HRP20240704TT patent/HRP20240704T1/en unknown
- 2017-05-10 EP EP24171718.0A patent/EP4411376A2/en active Pending
- 2017-05-10 US US16/301,019 patent/US20190178871A1/en active Pending
- 2017-05-10 ES ES17726208T patent/ES2826480T3/en active Active
- 2017-05-10 PL PL17726208T patent/PL3455625T3/en unknown
- 2017-05-10 RS RS20240614A patent/RS65568B1/en unknown
- 2017-05-10 HU HUE20193183A patent/HUE067497T2/en unknown
- 2017-05-10 AU AU2017264546A patent/AU2017264546B2/en active Active
- 2017-05-10 BR BR112018073221-4A patent/BR112018073221A2/en unknown
- 2017-05-10 WO PCT/EP2017/061196 patent/WO2017194610A1/en active Application Filing
- 2017-05-10 EP EP17726208.6A patent/EP3455625B1/en active Active
- 2017-05-10 DK DK20193183.9T patent/DK3792628T3/en active
- 2017-05-10 CA CA3022654A patent/CA3022654A1/en active Pending
- 2017-05-10 DK DK17726208.6T patent/DK3455625T3/en active
- 2017-05-10 LT LTEP20193183.9T patent/LT3792628T/en unknown
- 2017-05-10 SI SI201730466T patent/SI3455625T1/en unknown
- 2017-05-10 SI SI201731526T patent/SI3792628T1/en unknown
- 2017-05-10 CN CN201780026579.0A patent/CN109073637A/en active Pending
- 2017-05-10 SG SG11201808495SA patent/SG11201808495SA/en unknown
- 2017-05-10 JP JP2018559794A patent/JP7529381B2/en active Active
- 2017-05-10 LT LTEP17726208.6T patent/LT3455625T/en unknown
- 2017-05-10 EP EP20193183.9A patent/EP3792628B1/en active Active
- 2017-05-10 HU HUE17726208A patent/HUE052240T2/en unknown
- 2017-05-10 IL IL300841A patent/IL300841A/en unknown
- 2017-05-10 PT PT177262086T patent/PT3455625T/en unknown
- 2017-05-10 MX MX2018013081A patent/MX2018013081A/en unknown
- 2017-05-10 FI FIEP20193183.9T patent/FI3792628T3/en active
- 2017-05-10 KR KR1020227002915A patent/KR20220020993A/en active Application Filing
- 2017-05-10 KR KR1020187032652A patent/KR102358620B1/en active IP Right Grant
- 2017-05-10 PT PT201931839T patent/PT3792628T/en unknown
- 2017-05-10 KR KR1020247031632A patent/KR20240146087A/en active Search and Examination
- 2017-05-10 ES ES20193183T patent/ES2980781T3/en active Active
- 2017-05-10 MD MDE20190332T patent/MD3455625T2/en unknown
- 2017-05-10 RS RS20201233A patent/RS61071B1/en unknown
2018
- 2018-08-29 ZA ZA2018/05809A patent/ZA201805809B/en unknown
- 2018-10-25 MX MX2022007902A patent/MX2022007902A/en unknown
- 2018-10-29 IL IL262680A patent/IL262680B2/en unknown
2020
- 2020-10-14 CY CY20201100969T patent/CY1123520T1/en unknown
- 2020-10-16 HR HRP20201671TT patent/HRP20201671T1/en unknown
2022
- 2022-02-16 JP JP2022021751A patent/JP2022081492A/en active Pending
- 2022-07-27 AU AU2022209286A patent/AU2022209286A1/en active Pending
2024
- 2024-03-21 JP JP2024045130A patent/JP2024096712A/en active Pending
- 2024-04-23 JP JP2024069742A patent/JP2024112805A/en active Pending

Also Published As

Publication number	Publication date
HUE067497T2 (en)	2024-10-28
EP3455625A1 (en)	2019-03-20
JP2024112805A (en)	2024-08-21
SI3455625T1 (en)	2021-01-29
BR112018073221A2 (en)	2019-02-19
CN109073637A (en)	2018-12-21
RU2018137721A (en)	2020-06-15
IL262680B1 (en)	2023-04-01
SI3792628T1 (en)	2024-08-30
HRP20240704T1 (en)	2024-09-27
US20190178871A1 (en)	2019-06-13
LT3455625T (en)	2021-01-11
HRP20201671T1 (en)	2021-03-05
AU2017264546A1 (en)	2018-10-18
WO2017194170A1 (en)	2017-11-16
PL3792628T3 (en)	2024-07-15
DK3792628T3 (en)	2024-06-17
EP3792628B1 (en)	2024-04-24
CA3022654A1 (en)	2017-11-16
EP3455625B1 (en)	2020-09-02
JP2019520554A (en)	2019-07-18
ES2980781T3 (en)	2024-10-03
IL262680B2 (en)	2023-08-01
MX2018013081A (en)	2019-01-24
EP3792628A2 (en)	2021-03-17
IL262680A (en)	2018-12-31
RS61071B1 (en)	2020-12-31
ES2826480T3 (en)	2021-05-18
MX2022007902A (en)	2022-07-21
JP7529381B2 (en)	2024-08-06
WO2017194610A1 (en)	2017-11-16
MA43794B1 (en)	2020-12-31
AU2017264546B2 (en)	2022-04-28
MA43794A (en)	2019-03-20
FI3792628T3 (en)	2024-06-07
EP4411376A2 (en)	2024-08-07
PL3455625T3 (en)	2021-01-25
RS65568B1 (en)	2024-06-28
KR102358620B1 (en)	2022-02-07
KR20190008218A (en)	2019-01-23
MD3455625T2 (en)	2020-12-31
ZA201805809B (en)	2020-12-23
KR20220020993A (en)	2022-02-21
IL300841A (en)	2023-04-01
KR20240146087A (en)	2024-10-07
PT3455625T (en)	2020-10-22
LT3792628T (en)	2024-06-25
PT3792628T (en)	2024-06-18
JP2024096712A (en)	2024-07-17
RU2018137721A3 (en)	2020-08-25
CY1123520T1 (en)	2022-03-24
SG11201808495SA (en)	2018-10-30
HUE052240T2 (en)	2021-04-28
EP3792628A3 (en)	2021-05-19
JP2022081492A (en)	2022-05-31
AU2022209286A1 (en)	2022-08-25

Publication	Publication Date	Title
DK3512850T3 (en)	2023-07-03	INHIBITORS OF THE MENIN-MLL INTERACTION
DK3468966T3 (en)	2020-11-09	INHIBITORS OF THE MENIN-MLL INTERACTION
DK3192902T3 (en)	2019-07-15	PROCEDURE FOR THE MANUFACTURE OF GRAPHENCY VISCOSEFIBREES
DK3325443T3 (en)	2022-07-18	PROCEDURE FOR THE MANUFACTURE OF PRIDOPIDINE
DK3455625T3 (en)	2020-10-26	PROCEDURES FOR PREDICTING THE APPLICABILITY OF NEO ANTENGES FOR IMMUNTERAPHY
DK3096741T3 (en)	2020-09-28	PROCEDURE FOR THE PREPARATION OF HYBRIDOSOMES
DK3300500T3 (en)	2020-05-18	TRIAZOLAGONISTS OF THE APJ RECEPTOR
DK3512959T3 (en)	2021-10-18	Methods for performing multiplex PCR
DK3466432T3 (en)	2020-09-28	PROCEDURES FOR THE TREATMENT OF PULMONAL NON-TUBERCULOSE MICOBACTERIAL INFECTIONS
DK3286311T3 (en)	2021-05-17	PROCEDURE FOR TREATING MALIGNITIES
DK3072835T3 (en)	2019-07-29	PROCEDURE FOR PROCEDURE
DK3473783T3 (en)	2020-08-17	PROCEDURE FOR MAKING FLOOR TILES
DK3198035T3 (en)	2023-01-30	Methods for predicting drug response
DK3556775T3 (en)	2022-01-03	ANTI-LAG-3 ANTIBODIES FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIES
DK3174858T3 (en)	2019-07-15	PROCEDURE FOR THE PREPARATION OF PYRAZOLS
DK3294700T3 (en)	2020-04-14	PROCEDURE FOR PREPARING LIMONEN-4 OL
DK3940352T3 (en)	2023-09-04	PROCEDURE FOR DIAGNOSING WEIGHTS
DK3317400T3 (en)	2021-01-18	PROCEDURE FOR CRYO-PRESERVATION OF TUMOR-INFILRATING LYMPOCYTS
DK3317394T3 (en)	2024-01-22	DEVICE FOR PROPAGATION OF MICRO TISSUES
DK3344805T3 (en)	2022-03-07	PROCEDURE FOR SELECTING APTAMER FOR UNBINDED OBJECTIVES
DK3126373T3 (en)	2020-05-04	PROCEDURE FOR MANUFACTURING AMG 416
DK3186244T3 (en)	2020-07-13	DIOXOLANALOGS OF URIDINE FOR THE CANCER OF CANCER
DK3507408T3 (en)	2021-04-06	PROCEDURE FOR MAKING THE NONWOVEN
DK3233813T3 (en)	2022-03-07	PROCEDURES FOR THE PREPARATION OF OXATHIAZINE-LIKE COMPOUNDS
DK3529233T3 (en)	2020-10-12	PROCEDURE FOR PREPARING 3-ALKYLSULFANYL-2-CHLORO-N- (1-ALKYL-1H-TETRAZOL-5-YL) -4-TRIFLUOROMETHYL-BENZAMIDES